These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11103038)

  • 1. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100.
    Tremblay CL; Kollmann C; Giguel F; Chou TC; Hirsch MS
    J Acquir Immune Defic Syndr; 2000 Oct; 25(2):99-102. PubMed ID: 11103038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage.
    Kliger Y; Gallo SA; Peisajovich SG; Munoz-Barroso I; Avkin S; Blumenthal R; Shai Y
    J Biol Chem; 2001 Jan; 276(2):1391-7. PubMed ID: 11027678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
    Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
    Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV fusion and its inhibition.
    LaBranche CC; Galasso G; Moore JP; Bolognesi DP; Hirsch MS; Hammer SM
    Antiviral Res; 2001 May; 50(2):95-115. PubMed ID: 11369431
    [No Abstract]   [Full Text] [Related]  

  • 5. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
    Derdeyn CA; Decker JM; Sfakianos JN; Wu X; O'Brien WA; Ratner L; Kappes JC; Shaw GM; Hunter E
    J Virol; 2000 Sep; 74(18):8358-67. PubMed ID: 10954535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process.
    Bär S; Alizon M
    J Virol; 2004 Jan; 78(2):811-20. PubMed ID: 14694113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro.
    Vermeire K; Princen K; Hatse S; De Clercq E; Dey K; Bell TW; Schols D
    AIDS; 2004 Nov; 18(16):2115-25. PubMed ID: 15577644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death.
    Barretina J; Blanco J; Armand-Ugón M; Gutiérrez A; Clotet B; Esté JA
    Antivir Ther; 2003 Apr; 8(2):155-61. PubMed ID: 12741628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.
    Bianchi E; Finotto M; Ingallinella P; Hrin R; Carella AV; Hou XS; Schleif WA; Miller MD; Geleziunas R; Pessi A
    Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12903-8. PubMed ID: 16129831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors.
    Pan C; Lu H; Qi Z; Jiang S
    AIDS; 2009 Mar; 23(5):639-41. PubMed ID: 19242316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favorable interactions between enfuvirtide and 1-beta-D-2,6-diaminopurine dioxolane in vitro.
    Tremblay CL; Poulin DL; Hicks JL; Selliah S; Chamberland A; Giguel F; Kollmann CS; Chou TC; Dong H; Hirsch MS
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3644-6. PubMed ID: 14576137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.
    Liu S; Lu H; Niu J; Xu Y; Wu S; Jiang S
    J Biol Chem; 2005 Mar; 280(12):11259-73. PubMed ID: 15640162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV entry and fusion inhibitors.
    Chantry D
    Expert Opin Emerg Drugs; 2004 May; 9(1):1-7. PubMed ID: 15155132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs.
    Nakata H; Steinberg SM; Koh Y; Maeda K; Takaoka Y; Tamamura H; Fujii N; Mitsuya H
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2111-9. PubMed ID: 18378711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential for HIV fusion inhibition.
    Cammack N
    Curr Opin Infect Dis; 2001 Feb; 14(1):13-6. PubMed ID: 11979109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV co-receptor inhibitors as novel class of anti-HIV drugs.
    Schols D
    Antiviral Res; 2006 Sep; 71(2-3):216-26. PubMed ID: 16753228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro.
    Heredia A; Gilliam B; Latinovic O; Le N; Bamba D; Devico A; Melikyan GB; Gallo RC; Redfield RR
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2489-96. PubMed ID: 17485501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capture of an early fusion-active conformation of HIV-1 gp41.
    Furuta RA; Wild CT; Weng Y; Weiss CD
    Nat Struct Biol; 1998 Apr; 5(4):276-9. PubMed ID: 9546217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion.
    Nagashima KA; Thompson DA; Rosenfield SI; Maddon PJ; Dragic T; Olson WC
    J Infect Dis; 2001 Apr; 183(7):1121-5. PubMed ID: 11237840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.